Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 5/20 | 0.54 |
| ▸ | CRBN | Q96SW2 | 5/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.54 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.50 |
| ▸ | SRC | P12931 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.45 |
| ▸ | MC4R | P32245 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | MT-CO2 | P00403 | 3/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29716491 | 1.00 | DDB1 (0.54) | DDB1CRBNALDH1A1IKZF3CHRM2 | |
| SCHEMBL16140772 | 0.95 | CRBN (0.56) | DDB1CRBNALDH1A1IKZF3CHRM2 | |
| SCHEMBL22907414 | 0.85 | CRBN (0.54) | DDB1CRBNALDH1A1IKZF3CHRM2 | |
| SCHEMBL24266896 | 0.85 | DDB1 (0.42) | DDB1CRBNALDH1A1IKZF3CHRM2 | |
| SCHEMBL12988826 | 0.83 | CRBN (0.51) | DDB1CRBNALDH1A1IKZF3CHRM2 | |
| SCHEMBL17169709 | 0.77 | CRBN (0.57) | DDB1CRBNALDH1A1IKZF3CHRM2 | |
| SCHEMBL3125601 | 0.76 | CRBN (0.55) | DDB1CRBNALDH1A1IKZF3CHRM2 | |
| SCHEMBL18263933 | 0.76 | CRBN (0.55) | DDB1CRBNALDH1A1IKZF3CHRM2 | |
| SCHEMBL18935574 | 0.75 | ALDH1A1 (0.62) | DDB1CRBNALDH1A1IKZF3CHRM2 | |
| SCHEMBL18263934 | 0.75 | CRBN (0.82) | DDB1CRBNALDH1A1IKZF3CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022129256-A1 | SELECTIVE HDAC6 INHIBITOR | ROYAL COLLEGE OF SURGEONS IN IRELAND (IE) | 2022-06-23 | — | — | WO | disclosed |
| EP-2694472-B1 | SULFONAMIDE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2020-03-11 | — | — | EP | disclosed |
| US-9527807-B2 | Sulfonamide derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-12-27 | — | — | US | disclosed |
| EP-2694472-A2 | SULFONAMIDE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2014-02-12 | — | — | EP | disclosed |
| US-20140024650-A1 | SULFONAMIDE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-01-23 | — | — | US | disclosed |
| WO-2012137982-A9 | SULFONAMIDE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-02-14 | — | — | WO | disclosed |
| WO-2012137982-A2 | SULFONAMIDE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-11 | — | — | WO | disclosed |
| US-7763643-B2 | Substituted thiophenes: compositions, processes of making, and uses in disease treatment and diagnosis | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-07-27 | — | — | US | disclosed |
| US-20090137630-A1 | SUBSTITUTED THIOPHENES: COMPOSITIONS, PROCESSES OF MAKING, AND USES IN DISEASE TREATMENT AND DIAGNOSIS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-05-28 | — | — | US | disclosed |
| US-7488746-B2 | Substituted thiophenes: compositions, processes of making, and uses in disease treatment and diagnosis | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-02-10 | — | — | US | disclosed |
| US-20060160873-A1 | Substituted thiophenes: compositions, processes of making, and uses in disease treatment and diagnosis | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-07-20 | — | — | US | disclosed |
| US-7049333-B2 | Substituted thiophenes: compositions, processes of making, and uses in disease treatment and diagnosis | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-05-23 | — | — | US | disclosed |
| EP-1513834-B1 | SUBSTITUTED THIOPHENES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS A MEDICAMENT OR DIAGNOSTIC REAGENT, AND A MEDICAMENT CONTAINING THE SAME | SANOFI AVENTIS DEUTSCHLAND (DE) | 2006-03-15 | — | — | EP | disclosed |
| EP-1513834-A1 | SUBSTITUTED THIOPHENES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS A MEDICAMENT OR DIAGNOSTIC REAGENT, AND A MEDICAMENT CONTAINING THE SAME | Aventis Pharma Deutschland GmbH (DE) | 2005-03-16 | — | — | EP | disclosed |
| US-20040006119-A1 | Substituted thiophenes: compositions, processes of making, and uses in disease treatment and diagnosis | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-01-08 | — | — | US | disclosed |
| WO-2003101984-A1 | SUBSTITUTED THIOPHENES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS A MEDICAMENT OR DIAGNOSTIC REAGENT, AND A MEDICAMENT CONTAINING THE SAME | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-12-11 | — | — | WO | disclosed |
| US-6200991-B1 | M3-MUSCARINIC OR 5-HT SEROTONINERGIC RECEPTOR ANTAGONISTS; IRRITABLE BOWEL SYNDROME, INCONTINENCE, COGNITION ACTIVATORS; RESPIRATORY SYSTEM DISORDERS | SANOFI-SYNTHELABO (FR) | 2001-03-13 | — | — | US | disclosed |
| EP-1032569-A1 | IMIDAZOLE DERIVATIVES, PREPARATION AND THERAPEUTIC APPLICATION THEREOF | SANOFI-SYNTHELABO (FR) | 2000-09-06 | — | — | EP | disclosed |
| WO-1999031097-A1 | IMIDAZOL DERIVATIVES AS MUSCARINIC M3 RECEPTOR ANTAGONISTS | SANOFI-SYNTHELABO (FR) | 1999-06-24 | — | — | WO | disclosed |
| WO-1999025710-A1 | IMIDAZOLE DERIVATIVES, PREPARATION AND THERAPEUTIC APPLICATION THEREOF | SANOFI-SYNTHELABO (FR) | 1999-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137630-A1 | SUBSTITUTED THIOPHENES: COMPOSITIONS, PROCESSES OF MAKING, AND USES IN DISEASE TREATMENT AND DIAGNOSIS | PLAT, CPS1, TST | DDB1 1848/4885CRBN 2745/4885ALDH1A1 429/4885 |
| US-20040006119-A1 | Substituted thiophenes: compositions, processes of making, and uses in disease treatment and diagnosis | TST, GOT2, ALPP | DDB1 1680/4885CRBN 2627/4885ALDH1A1 386/4885 |
| US-20060160873-A1 | Substituted thiophenes: compositions, processes of making, and uses in disease treatment and diagnosis | PLAT, TST, PNLIP | DDB1 1544/4885CRBN 2329/4885ALDH1A1 400/4885 |
| US-20140024650-A1 | SULFONAMIDE DERIVATIVE AND USE THEREOF | GRIN2A, GRIN2B, SLC1A2 | DDB1 2766/4885CRBN 3329/4885ALDH1A1 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.